Ketamine-Assisted Psychotherapy (KAP) for Postpartum Depression
An Open-Label Single-Arm Clinical Study
Ketamine has been recognized for its ability to quickly disrupt major depressive disorder and treatment-resistant depression.
Racemic ketamine may provide rapid relief for postpartum depression while first-line pharmaceutical options remain limited by 6-8 week timelines and unpredictable outcomes.
Racemic ketamine is currently available for depression as an off-label prescription and is typically denied coverage by insurance carriers for this reason. In an effort to make KAP more accessible, Deva Collective is conducting a Single-Arm, Open-Label Trial using racemic ketamine for postpartum depression.
Our research aims to demonstrate the efficacy of intramuscular racemic ketamine as an alternative to Spravato, Johnson & Johnson’s FDA-approved esketamine nasal spray for depression. Unlike racemic ketamine, which has more established lactation safety data, Spravato has limited evidence supporting its use during breastfeeding and may require concurrent treatment with an oral antidepressant.
Our investigation of KAP for postpartum depression is a philanthropic opportunity where the return on investment is collective and societal. When we care for mothers, we care for families and communities.
By contributing clinical evidence to the medical field, we urge insurance companies to cover racemic ketamine when used in the treatment of depression.
“Ketamine helps people recover, remember, or discover their own inner healing intelligence. It helps them hold the possibility that things can be different; they don’t have to be stuck where they are. This reality can be built upon in psychotherapy after the ketamine session ends.”
